Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 127851 | Other Identifier | Western HSREB Project ID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this pilot clinical trial is to learn if a faster brain stimulation schedule is practical, safe, tolerable, and acceptable. This study looks at accelerated intermittent theta burst stimulation, or accelerated iTBS. This is a non-invasive type of magnetic brain stimulation. This study is for adults with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).
The main questions this study aims to answer are:
Participants will:
This is a single-arm, open-label pilot feasibility study of accelerated intermittent theta burst stimulation, also called accelerated iTBS, in adults with both post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The study is designed to assess whether an accelerated iTBS schedule can be delivered safely, tolerably, and feasibly in a clinical setting. The main focus is feasibility, including recruitment, treatment adherence, participant retention, safety, tolerability, and participant acceptability. About 12 to 16 participants will receive active accelerated iTBS. Treatment will include six short stimulation sessions per day over five consecutive days, for a total of 30 sessions. The study will also collect exploratory information over time on depression symptoms, PTSD symptoms, anxiety, daily functioning, quality of life, and brain activity measured by EEG. Because this is a small pilot study, the analysis will be mainly descriptive. The results will help refine study procedures and guide the design of a larger future clinical trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Accelerated iTBS | Experimental | Participants will receive active accelerated intermittent theta burst stimulation (iTBS). Treatment will consist of six short stimulation sessions per day delivered over five consecutive days, for a total of 30 sessions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Accelerated intermittent theta burst stimulation | Device | Accelerated intermittent theta burst stimulation, also called accelerated iTBS, is a non-invasive magnetic brain stimulation intervention. Stimulation is delivered to the left dorsolateral prefrontal cortex using a transcranial magnetic stimulation system. Participants receive six short sessions per day over five consecutive days. |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment rate | Recruitment rate will be assessed as the number of participants enrolled per month during the active recruitment period. | Study recruitment period, up to 12 months |
| Consent rate | Consent rate will be assessed as the proportion of eligible individuals approached who provide informed consent. | Study recruitment period, up to 12 months |
| Treatment adherence | Treatment adherence will be assessed as the percentage of scheduled accelerated iTBS sessions completed during the 5-day treatment course. | Treatment Days 1 through 5 |
| Retention through Week 12 follow-up | Retention will be assessed as the proportion of enrolled participants who complete the Week 12 follow-up visit. | Baseline through Week 12 |
| Adverse events | Adverse events will be assessed as the proportion of participants who experience one or more adverse events during treatment and follow-up. | Treatment Days 1 through Week 12 |
| Serious adverse events | Serious adverse events will be assessed as the proportion of participants who experience one or more serious adverse events during treatment and follow-up. | Treatment Days 1 through Week 12 |
| Discontinuations due to adverse events | Tolerability will be assessed as the proportion of participants who discontinue accelerated iTBS because of adverse events. |
| Measure | Description | Time Frame |
|---|---|---|
| Exploratory change in clinician-rated depression symptom severity measured by HAMD-17 | Clinician-rated depression symptom severity will be assessed using the Hamilton Depression Rating Scale-17. Total scores range from 0 to 52, with higher scores indicating greater depression symptom severity. | Baseline, Week 2, Week 5, and Week 12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Radhika Kelkar, MD | Contact | 519-685-8500 | 75805 | radhika.kelkar@lhsc.on.ca |
| Mervin Blair, PhD, C.Psych | Contact | 519-646-6100 | 48170 | mervin.blair@sjhc.london.on.ca |
| Name | Affiliation | Role |
|---|---|---|
| Radhika Kelkar, MD | St. Joseph's Health Care London, Parkwood Institute, Finch Family Mental Health Care Building | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Joseph's Health Care London, Parkwood Institute Mental Health Care Building | London | Ontario | N6C 0A7 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003130 | Combat Disorders |
| D003865 | Depressive Disorder, Major |
| D013313 | Stress Disorders, Post-Traumatic |
| D003863 | Depression |
| ID | Term |
|---|---|
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
| D001523 | Mental Disorders |
| D003866 | Depressive Disorder |
Not provided
Not provided
Single-arm pilot feasibility study evaluating an intensive accelerated iTBS protocol.
Not provided
Not provided
Not provided
Not provided
|
| Treatment Days 1 through Week 12 |
| Participant satisfaction with accelerated iTBS | Participant satisfaction will be assessed using a 5-point Likert satisfaction rating scale. Scores range from 1 to 5, with higher scores indicating greater satisfaction. | Week 2, Week 5, and Week 12 |
| Participant feedback on accelerated iTBS | Participant feedback will be assessed using brief feedback questions about the accelerated iTBS treatment schedule and overall study experience. Responses will be summarized descriptively. | Week 2, Week 5, and Week 12 |
| Exploratory change in self-reported depression symptom severity measured by PHQ-9 |
Self-reported depression symptom severity will be assessed using the Patient Health Questionnaire-9. Total scores range from 0 to 27, with higher scores indicating greater depression symptom severity. |
| Baseline, Week 2, Week 5, and Week 12 |
| Exploratory change in self-reported PTSD symptom severity measured by PCL-5 | Self-reported PTSD symptom severity will be assessed using the PTSD Checklist for DSM-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. | Baseline, Week 2, Week 5, and Week 12 |
| Exploratory change in clinician-rated PTSD symptom severity measured by CAPS-5 | Clinician-rated PTSD symptom severity will be assessed using the Clinician-Administered PTSD Scale for DSM-5. Total symptom severity scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. | Baseline, Week 2, and Week 12 |
| Exploratory change in anxiety symptom severity measured by GAD-7 | Anxiety symptom severity will be assessed using the Generalized Anxiety Disorder-7 item Scale. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. | Baseline, Week 2, Week 5, and Week 12 |
| Exploratory change in cognitive function measured by MoCA | Cognitive function will be assessed using the Montreal Cognitive Assessment. Total scores range from 0 to 30, with higher scores indicating better cognitive function. | Baseline, Week 2, Week 5, and Week 12 |
| Exploratory change in functioning and disability measured by WHODAS 2.0 | Functioning and disability will be assessed using the WHO Disability Assessment Schedule 2.0 | Baseline, Week 2, Week 5, and Week 12 |
| Exploratory change in quality of life measured by Q-LES-Q-SF | Quality of life will be assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form. | Baseline, Week 2, Week 5, and Week 12 |
| Baseline clinical global severity measured by CGI-S | Clinical global severity will be assessed using the Clinical Global Impression-Severity scale. Scores range from 1 to 7, with higher scores indicating greater illness severity. | Baseline |
| Exploratory change in clinical global improvement measured by CGI-I | Clinical global improvement will be assessed using the Clinical Global Impression-Improvement scale. Scores range from 1 to 7, with lower scores indicating greater clinical improvement. | Week 2, Week 5, and Week 12 |
| Exploratory change in resting-state EEG alpha power | Resting-state EEG alpha power recorded at frontal electrodes will be assessed using EEG recordings collected at baseline and on treatment Days 1 and 5. On Days 1 and 5, brief resting-state EEG recordings will be collected immediately before and after each iTBS session to explore neurophysiological changes associated with accelerated iTBS. | Baseline, Treatment Day 1, and Treatment Day 5 |
| Exploratory change in resting-state EEG gamma power | Resting-state EEG gamma power recorded at frontal electrodes will be assessed using EEG recordings collected at baseline and on treatment Days 1 and 5. On Days 1 and 5, brief resting-state EEG recordings will be collected immediately before and after each iTBS session to explore neurophysiological changes associated with accelerated iTBS. | Baseline, Treatment Day 1, and Treatment Day 5 |
| D019964 | Mood Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |